Bio-Techne stock kpis
Want to see TECH full AI Analyst Report?
Revenue by Geography
Bio-Techne reported revenue by region of $316.96M in Q4 FY2025, up 0.2% from Q3 FY2025 and up 3.5% year over year. This is the highest value since 2020.
Breaks down sales across regions so you can see where the company’s demand is strongest and where it faces exposure to local economic cycles, regulatory changes, or currency swings. Helps gauge geographic diversification and where future growth or risk is concentrated.
Bio-Techne's revenue growth in the United States and EMEA regions remains robust, reflecting strong demand in biopharma markets. Greater China shows signs of recovery with low double-digit growth, aligning with earnings call optimism about stabilization. However, the Rest of World and UK regions face challenges, possibly due to geopolitical and funding uncertainties. The strategic divestiture of Exosome Diagnostics is expected to enhance margins, supporting future profitability despite current market uncertainties.
No longer reported by the company (last reported Q4 FY2025)
TECH Revenue by Geography
| Period | United States | Greater China | Rest of World | United Kingdom | Europe, Middle East, and Africa (excluding UK) | APAC (excluding Greater China) | Total |
|---|---|---|---|---|---|---|---|
| Q4 FY2025Jun 30, 2025 | $176.39M | $26.91M | $9.65M | $14.79M | $70.35M | $18.89M | $316.96M |
| Q3 FY2025Mar 31, 2025 | $181.92M | $24.48M | $9.18M | $12.85M | $66.50M | $21.25M | $316.18M |
| Q2 FY2025Dec 31, 2024 | $159.91M | $24.75M | $9.73M | $13.24M | $70.39M | $19.01M | $297.03M |
| Q1 FY2025Sep 30, 2024 | $165.01M | $24.32M | $8.99M | $13.94M | $59.06M | $18.12M | $289.46M |
| Q4 FY2024Jun 30, 2024 | $177.53M | $23.93M | $10.05M | $11.77M | $63.56M | $19.26M | $306.10M |
| Q3 FY2024Mar 31, 2024 | $173.31M | $25.60M | $10.61M | $15.12M | $60.53M | $18.25M | $303.43M |
| Q2 FY2024Dec 31, 2023 | $147.79M | $24.46M | $8.09M | $10.68M | $62.54M | $19.04M | $272.60M |
| Q1 FY2024Sep 30, 2023 | $159.10M | $25.48M | $7.75M | $12.45M | $54.80M | $17.35M | $276.94M |
| Q4 FY2023Jun 30, 2023 | $174.83M | $25.77M | $10.07M | $13.07M | $59.98M | $17.60M | $301.32M |
| Q3 FY2023Mar 31, 2023 | $163.20M | $26.26M | $11.02M | $13.81M | $59.70M | $20.16M | $294.15M |
| Q2 FY2023Dec 31, 2022 | $149.00M | $30.33M | $8.89M | $10.87M | $54.52M | $17.97M | $271.58M |
| Q1 FY2023Sep 30, 2022 | $155.43M | $31.52M | $7.51M | $11.70M | $46.02M | $17.46M | $269.65M |
| Q4 FY2022Jun 30, 2022 | $167.06M | $26.44M | $10.34M | $11.40M | $55.05M | $17.93M | $288.23M |
| Q3 FY2022Mar 31, 2022 | $163.98M | $26.55M | $10.53M | $12.92M | $55.30M | $21.10M | $290.38M |
| Q2 FY2022Dec 31, 2021 | $142.37M | $31.01M | $7.30M | $11.84M | $57.16M | $19.60M | $269.28M |
| Q1 FY2022Sep 30, 2021 | $140.70M | $28.43M | $7.06M | $12.48M | $51.54M | $17.50M | $257.72M |
| Q4 FY2021Jun 30, 2021 | $142.49M | $23.87M | $8.40M | $11.35M | $56.64M | $16.27M | $259.03M |
| Q3 FY2021Mar 31, 2021 | $131.59M | $20.47M | $6.73M | $11.21M | $54.55M | $19.00M | $243.55M |
| Q2 FY2021Dec 31, 2020 | $114.44M | $25.16M | $6.85M | $9.85M | $49.94M | $18.01M | $224.25M |
| Q1 FY2021Sep 30, 2020 | $113.56M | $18.05M | $5.18M | $8.53M | $43.13M | $15.73M | $204.20M |

